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BACKGROUND
Delayed wound healing is a huge drain on healthcare 
budgets, and chronic wounds are estimated to account 
for 2-4% of global healthcare costs (1), or approxi-
mately €100-200 billion per year (2). h e develop-
ment of infection delays the normal wound healing 
process and results in increased burden on the patient 
and caregiver alike (3,4). Clinical infection develops 
when the body’s innate immune defence mechanisms 
respond to the presence and invasion of pathogens, 
including endotoxin and exotoxin produced by the 
microorganisms themselves (5), via local inl amma-
tory processes (6). h ese result in the familar, classic 
signs of wound infection – redness, heat, swelling, 
pain, odor, pus, as well as the more recently acknowl-
edged addional signs, such as friable granulation tis-
sue, discolouration, and delay to timely wound healing 
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(4). However, in the last 10-15 years, another factor 
in wound infection and delayed healing has emerged. 
h e presence and development of microbial bioi lm 
in wounds has been proposed (7,8), investigated (9), 
and then scientii cally coni rmed in chronic wounds 
(10,11). 
Bioi lm in wounds are communities of microrganisms 
adhered to each other and to wound surfaces, such 
as the wound bed, devitalised tissue, or dressings. 
h e microorganisms are embedded in a matrix of ex-
tra-cellular polymeric substances (EPS), comparised 
mainly of polysaccharides, proteins and DNA, form-
ing a complex, three-dimensional scaf old of slime in 
which they are protected (12). Bioi lm microorgan-
isms are thus physically protected in the slime, and 
also display slower growth rates and metabolic phe-
notypes than their planktonic counterparts (13). As a 
result, bioi lm microorganisms can display tolerance 
towards systemic antibiotics and topically-applied an-
tiseptics, such as silver or iodine (14), as well as host 
defence mechanisms, such as phagocytosis and en-
zyme-mediated microbial killing by neutrophils (15). 
Figure 1 shows how planktonic, single-celled micro-
organisms, can attach to wound surfaces and, if not 
managed at this stage by an optimal host immune re-
sponse or by antimicrobial agents, the microorganisms 
will secrete their sticky bioi lm matrix. At this stage 
the bioi lm will be microscopic but may start to illicit 
an inl ammatory host response, and if unchecked, can 
develop into larger, more elaborate communities (16). 
At this stage, bioi lm may be visible directly as slimy or 
milky substances on the wound bed, or indirectly via 
the signs of inl ammation or infection which they illic-
it (17,18). Established wound bioi lm therefore pres-
ents a serious infection risk, and may also seed bioi lm 
formation elsewhere in the wound (19). As bioi lm 
develops, so the risk of infection and delayed healing 
increases (Fig. 1).
Contamination Colonisation Bioi lm development; Possible infection; Inl ammatory host response Local spreading
Fig. 1. Bioi lm formation in wounds (originally published in (42).
A growing body of scientii c and clinical evidence 
now exists which suggests that wound bioi lm, if not 
properly managed, may lead to wound infection and 
can delay healing (20). Dr Randall Wolcot, who prac-
tices bioi lm-based wound care (BBWC) (21) in the 
US has stated that “bioi lms are the principle cause of 
wound chronicity” (22). Whilst this statement has yet 
to be fully verii ed, the evidence that BBWC – the use 
of multiple, concurrent physical debridement and an-
timicrobial methods to target bioi lm – can accelerate 
progression towards healing (23,24), with associated 
cost benei ts (25), is growing. Scientii c research within 
the last decade has coni rmed that bioi lm presence is 
correlated with wound chronicity, beginning in 2008, 
when two pioneering research groups in the US (10) 
and Denmark (11) independently observed bioi lm 
microscopically in 60% of chronic wound samples. 
Further powerful scientii c evidence comes from in vivo 
animal models, for example, by the introduction of bio-
i lm into carefully-created acute leporine ear wounds, 
which can then be monitored to evaluate the ei  cacy of 
anti-bioi lm approaches (26). In this model, inef ective 
host inl ammatory responses have been observed, such 
as failure of neutrophils to phagocytose (26) and kill 
pathogens via the oxidative burst (27), and well as dif-
ferential inl ammatory responses ellicited by dif erent 
pathogenic bioi lm species (28). h e healing procesess 
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of granulation tissue formation and epithelialization 
have also been shown to be retarded by the presence 
of bioi lm in the wound bed (26,28,29). Notably, using 
multiple concurrent strategies to target bioi lm in this 
model has been shown to be more ef ective at encour-
aging wound healing than individual techniques (30). 
h e emerging problem of wound bioi lm presents a sig-
nii cant challenge for developers of new, more ef ective 
wound dressings. h e aim of this review is to summa-
rize the development of a new dressing technology de-
signed to be ef ective against wound bioi lm.
DESIGNING A NEW ANTI-BIOFILM 
TECHNOLOGY
Formulation
h e market-leading antimicrobial wound dressing, a 
nonwoven carboxymethylcelluose (CMC) dressing 
containing 1.2% ionic silver (AQUACEL™ Ag), has 
been on the market since 2002, before the ‘bioi lm 
era’ of wound care really began (8-11). Although this 
dressing shows some ef ectiveness against bioi lm in 
laboratory models (31,32), its silver ions, unaided, are 
slow to reach the microorganisms protected within the 
bioi lm. When considering how to make ionic silver 
far more ef ective against bioi lm, simply adding high-
er concentrations of silver would have safety implica-
tions (33) and would alter the physical attributes of 
the CMC dressing (exudate absorption and retention, 
gelling, conformability to the wound bed, etc.) (34). 
A comprehensive research and development program 
i rstly focused on understanding the general structure, 
composition and behaviour of wound bioi lm. Know-
ing that the complex three-dimensional matrix of 
EPS was generally comprised of hydrated polysaccha-
rides, protein and DNA of microbial origin, as well as 
host-derived devitalised tissues (12,35), the search for 
safe and ef ective means by which to target this matrix 
was undertaken. h e hypothesis was that if the bioi lm 
matrix could be destabilized and the microorganisms 
within be exposed, then the antimicrobial activity of 
the silver CMC base dressing would be maximized.
Several modes of action of bioi lm destabilization were 
theorized, such as enzymatic action, solubilization, ion 
exchange, metal chelation, ionic and nonionic surfactan-
cy, and pH control. Following tens of thousands of lab-
oratory tests using a well-characterized rapid screening 
assay for anti-bioi lm activity (36), an optimum combi-
nation of low levels of metal chelator and a surfactant, 
combined with pH control was identii ed. When formu-
lated with 1.2% ionic silver, this combination demon-
strated highly synergistic anti-bioi lm activity. h e metal 
chelator was selected due to its ability to sequester di-
valent metal ions, such as Fe2+, Ca2+ and Mg2+, which 
are known to hold the polymers of the bioi lm matrix 
scaf old together (37,38). h e surfactant selected has a 
detergent-like action which further loosens the bioi lm, 
reducing surface tensions within the dressing and bio-
i lm, allowing the ionic silver to move more quickly (39). 
Finally, an acidic pH of 5.5 was identii ed as optimum 
in order for the other new components and ionic silver 
to function most ef ectively (40,41). Notably, the CMC 
remained the same, and the level of silver remained the 
same as in the original silver CMC dressing (1.2%). 
EVIDENCE FOR A NEW ANTI-BIOFILM 
TECHNOLOGY
Anti-bioi lm ef ectiveness testing
h is unique formulation of anti-bioi lm excipients 
and ionic silver was named ‘Ag+ Technology’, and its 
ef ectiveness was verii ed following manufacture into 
the CMC dressing form (CMC-Ag+) using a complex 
in vitro gauze bioi lm model. Briel y, mature commu-
nity-associated Methicillin-resistant Staphylococcus 
aureus (CA-MRSA) or Pseudomonas aeruginosa bio-
i lm was grown on gauze dressing pieces, before being 
transferred to agar plates (simulating the wound bed) 
mounted in a leather surround (simulating the peri-
wound skin). h e dressing was then applied to the bio-
i lm, a secondary dressing applied, and its anti-bioi lm 
performance assayed at frequent time points by viable 
counting and microscopic image analysis. Compared to 
the base silver CMC dressing (42), and two other com-
mercially-available silver dressings containing 2.2% 
and 11.2% silver (43), the CMC-Ag+ dressing showed 
signii cantly superior ef ectiveness against CA-MRSA 
and P. aeruginosa bioi lm, in terms of bacterial killing 
and prevention of bioi lm re-reformation following 
re-inoculation (Table 1). h is ef ectiveness was subse-
quently coni rmed in an independent model that used 
microcalorimetry to measure anti-bioi lm activity via 
changes in total bioi lm metabolism (44) (Table 1). 
h e safety and performance of the CMC-Ag+ dress-
ing was evaluated in external toxicity and performance 
studies, as required by regulatory authorities, includ-
ing in a well-characterized in vivo model (26). Briel y, 
P. aeruginosa bioi lm, or P. aeruginosa and S. aureus 
polymicrobial bioi lm, was allowed to develop in acute 
wounds of dei ned size, and the ef ect of the applied 
CMC-Ag+ was measured by viable counts and the 
wound closure parameters of granulation tissue forma-
tion and epithelialization. h e dressing was found to 
be signii cantly superior to a polyhexanide-containing 
antimicrobial dressing in reducing bioi lm counts and 
achieving wound healing progression (45) (Table 1). 
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Table 1.
Summary of initial in vitro, in vivo and clinical studies for the CMC-Ag+ dressing (42-47). 1: AQUACEL® Ag (ConvaTec); 2: 
Silvercel™ Non Adherent (Systagenix, UK); 3: Acticoat™ 7 (Smith & Nephew, UK); 4: AQUACEL® (ConvaTec); 5: Telfa™ AMD™ 
(Covidien, US).
Study type Model Comparators Results Reference
In vitro Gauze biofi lm model; viable biofi lm counts Silver (1.2%) CMC dressing1
CMC-Ag+ dressing gave 6 log
10
 kill of P. 
aeruginosa and CA-MRSA biofi lm after 4 
and 5 days; standard silver CMC did not fully 
eradicate either biofi lm
42
In vitro Gauze biofi lm model; viable biofi lm counts
(i) Silver (2.2%) alginate-CMC-nylon 
dressing2; 
(ii) nanocrystalline silver (11.2%) rayon-
polyester-polyethylene dressing3
Silver alginate-CMC-nylon dressing and 
nanocrystalline silver dressing did not reduce 
P. aeruginosa or CA-MRSA biofi lm counts
43
In vitro
Agar-supported biofi lm; isothermal 
microcalorimetry
(i) CMC dressing4; 
(ii) silver (1.2%) CMC dressing1; (ii) 
silver nitrate solution (0.1 M); (iv) 
ethylenediaminotetraacetic acid (EDTA; 
metal chelator); 
(v) benzethonium chloride (BC; surfactant)
CMC-Ag+ dressing and silver 
nitrate+EDTA+BC eradicated S. aureus 
biofi lm; silver CMC dressing, CMC dressing, 
EDTA+BC, and silver nitrate alone did not 
eradicate the biofi lm; demonstrating synergy 
of silver with metal chelator and surfactant
44
In vivo
(i) Polyhexanide gauze dressing5; (ii) CMC 
dressing4
CMC-Ag+ dressing gave 2 log
10
 reductions 
in P. aeruginosa biofi lm after 4 and 6 days 
compared to polyhexanide gauze and CMC 
dressings; granulation tissue formation and 
epithelialization was signifi cantly better 
in CMC-Ag+ dressed wounds; similar 




Clinical safety & performance in venous 
leg ulclers
None
Acceptable safety profi le demonstrated; 
after 4 weeks CMC-Ag+ dressing then 4 
weeks CMC 12% of wounds healed, 76% 
showed improvement in wound health; mean 
ulcer size reduction was 55%; subset of 10 




Evaluations in chronic and acute wounds
None (previously used primary dressings 
were recorded)
CMC-Ag+ dressing resulted in an average 
wound closure of 73% after average of 4.1 
weeks; 17% of wounds healed
47
Clinical assessment 
h e CMC-Ag+ dressing was also evaluated clinically 
in two separate investigations. h e i rst was primarily a 
clinical safety study involving 42 patients with venous 
leg ulcers, of which 10 were deemed to be clinically 
infected. Whilst safety and progress towards wound 
closure was demonstrated for all wounds, in particu-
lar the 10 infected wounds, where bioi lm was likely a 
factor, responded in more dramatic fashion, following 
4 weeks of management with the CMC-Ag+ dressing 
then 4 weeks with the base CMC dressing (46; Table 
1). Clinical evaluations on this now CE-Marked dress-
ing were also conducted across Europe and Canada, 
where 113 hard-to-heal wounds were selected based 
on suspicion of infection (4) or bioi lm (17) based on 
clinical signs. At er an average of 4.1 weeks use of the 
CMC-Ag+ dressing in otherwise standard care proto-
cols, 73% average wound closure was achieved, with 
17% of wounds progressing to complete healing (47) 
(Table 1). 
New clinical evidence 
h e version of this dressing designed to manage wound 
bioi lm that is now commercially-available in Europe 
and Canada since 2014, AQUACEL® Ag+ EXTRA™ 
(CMC-Ag+E), is thicker to give improved absorption 
and also contains strengthening yarn to aid complete 
dressing removal (42). Since its launch, post-market 
survelliance evaluations have been conducted in the 
United Kingdom to further investigate the safety and 
ef ectiveness of the dressing. Clinicians in healthcare 
facility and community settings across the UK were 
invited to select challenging cases of hard-to-heal 
wounds that were stalled or deteriorating, and that 
might be compromised by infection (4) or suspected 
bioi lm (17). Clinicians were asked to consider switch-
ing the previously used primary antimicrobial dressing 
to CMC-Ag+E for to 4 weeks, or as long as they con-
sidered it appropriate. All other standard local proto-
cols were followed, and the clinicians recorded patient 
and various wound data throughout the evaluations on 
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simple forms. Two data sets emerged; the i rst was a 
112-case population where safety and ef ectivess could 
be examined using baseline and post-evaluation data 
on exudate, wound bed appearance (including suspect-
ed bioi lm), wound progression, and dressing-related 
adverse events. A smaller data set of 29 cases where 
pre- and post-evalution data on signs of infection and 
wound dimensions were also available. 
Safety & ef ectiveness 
Baseline and post-evaluation data from the 112-case 
clinical evaluation is summarized in Table 2. Most of 
the wounds were stagnant with over a quarter classed 
as deteriorating at baseline. Almost one-third were 
judged to be infected, and bioi lm suspicion of 54% 
was greater than any other individual clinical sign of 
infection (data not shown). Duration of use of the 
CMC-Ag+E dressing was less than 4 weeks on av-
erage. Exudate levels, which were previously high 
or medium, were shit ed to low or medium. Bioi lm 
suspicion, as judged by visible or indirect signs (17), 
was more than halved. In terms of the wound bed ap-
pearance, before the evaluations, the main tissue type 
observed was suspected bioi lm or slough. At er use of 
the CMC-Ag+E dressing, this suspected bioi lm and 
slough was reduced, while granulation tissue had be-
come the main wound bed tissue type. Notably, these 
stalled and deteriorating wounds were shit ed onto 
healing trajectories, with a majority of the wounds 
improving and 14 healing completely. Perhaps most 
importantly, there were only a small number of dress-
ing-related adverse events. Only 3 such events were 
identii ed, and 2 of these were mild stinging which re-
solved quickly. h ere was one unexplained ‘reaction‘ 
to the dressing, but overall, the CMC-Ag+E dressing 
was well tolerated and appeared to have an acceptable 
safety proi le, as had been previously determined (46). 
Table 2. 
Summary of new clinical evidence for the CMC-Ag+E dressing.
Data set 1 Data set 2 (48)
Baseline data
Number of wounds 112 (111 patients) 29 (28 patients)







Classed as clinically infected 31% 24%
Biofi lm suspicion (yes/no judgment) 54% 76%
Results
Mean dressing use duration 3.9 weeks 5.4 weeks
Exudate rating Before
After 
54% medium, 43% high
48% low, 44% medium
55% medium, 34% high
41% medium, 34% low
Main wound bed tissue Before
types (% judgment) After
40% suspected biofi lm, 31% slough
 46% granulation tissue, 17% slough
49% suspected biofi lm, 27% slough
53% granulation tissue, 24% biofi lm






Signs of infection (+ biofi lm) Before





Wound closure 65% improved, 13% healed 90% improved, 34% healed, 62% average wound closure
Adverse events 3 (2 mild stinging, 1 unknown ‘reaction‘) N/A
Infection and wound closure 
Baseline and post-evaluation data from the 29 cases 
where signs of infection and wound closure data was 
also available is summarized in Table 2 (48). Baseline 
data was generally similar to the larger study, with 
a majority of wounds stagnant and approximately 
one-quarter deteriorating, although clinical infec-
tion classii cation was slightly lower at one-quarter of 
wounds, while bioi lm suspicion higher at 76%. Dura-
tion of dressing usage was 5.4 weeks on average, and 
as in the larger study, exudate levels were reduced af-
ter the evaluations, and wound bed tissue types were 
shit ed from suspected bioi lm and slough to mainly 
granulation tissue. In addition to suspected bioi lm, 
the frequency of 8 clinical signs of infection were re-
corded (erythema, oedema, heat/warmth, pain, odour, 
excessive exudate, and discolured or friable granula-
tion tissue) (4). For each of these signs, frequency was 
reduced following the dressing evaluations, with the 
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average frequency reducing from 36% to 21%. Wound 
closure data available for these 29 cases shows that 10 
wounds completely healed and 90% reduced in size, 
with an average closure of 62% achieved. h e wounds 
that fully healed were, on average, 14 months in dura-
tion yet it took just 6.7 weeks on average to heal these 
wounds using the CMC-Ag+E dressing (48). Upon in-
vestigation of 3 wounds which did not get smaller, it 
was found that 2 were from the same patient who was 
being administered systemic antibiotics, and the other 
was a long-standing wound of 7 years in a patient with 
peripheral arterial disease. h is new clinical data on 
the ef ectiveness of this next-generation antimicrobial 
wound dressing to not only manage exudate, infection 
and bioi lm, but to also shit  challenging wounds onto 
healing trajectories, provides further evidence for this 
specii cally developed new anti-bioi lm technology.
CONCLUSION
h e development of a next-generation antimicrobial 
wound dressing, based on the new i eld of wound bio-
i lmology, has been shown to be ef ective in a num-
ber of in vitro, in vivo and clinical studies/evaluations. 
h e dressing combines ef ective anti-bioi lm action, 
enabling the activity of the well-established, safe an-
timicrobial agent, ionic silver, with a moist wound 
healing environment provided by the CMC dressing 
base. Emerging clinical evidence suggests that this 
dressing is able to shit  challenging wounds onto heal-
ing trajectories where other antimicrobial therapies 
have not. h is early promise should be investigated to 
understand the potential costs savings – wound care 
products, antibiotics (49), clinician time, clinical stay 
costs, etc. (50) – associated with the use of a dressing 
which progresses chronic wounds towards healing or 
resolves infected wounds. Comparative, randomized 
and outcome-based studies may provide even stron-
ger clinical evidence for this new dressing technology. 
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Odgođeno cijeljenje rana zbog infekcije je teret zdravstvenim sustavima, a jednako tako i pacijentu i onome koji skrbi za 
njega. Bitan čimbenik u nastajanju infekcije i odgođenog cijeljenja je razvoj i prisutnost biofi lma u ranama. Biofi lm je zajednica 
mikroorganizama, zaštićena izvanstaničnim sluzavim matriksom u rani, koji može tolerirati obranu domaćina i primijenjena 
antimikrobna sredstva, kao što su antibiotici ili antimikrobne obloge. Rastući broj znanstvenih dokaza upućuje da biofi lm 
već egzistira u većini kroničnih rana, a može biti i prethodnik infekciji dok istodobno uzrokuje odgođeno cijeljenje. In vivo 
modeli pokazali su da su upala, granulacija i epitelizacija, te procesi normalnog cijeljenja rane narušeni prisustvom biofi lma. 
Izazov u razvoju nove antimikrobne obloge za ranu bio je da standardna antimikrobna sredstva učinimo učinkovitija protiv 
biofi lma, a rješenje je uslijedilo nakon opsežnih istraživanja i ispitivanja biofi lma. Kombinacija metalnog kelatora, površinski 
aktivne tvari i kontrole pH faktora pokazala je snažnu sinergističku anti-biofi lm akciju u oblozi od karboksimetilceluloze sa 
1,2 % ionskog srebra. Ta je učinkovitost testirana i dokazana u kompleksnim in vitro i in vivo modelima rana s biofi lmom, 
a zatim i u klinički kontroliranim studijama, i to u studiji na 42-pacijenta i 113 kliničkih evaluacija. Naknadno ispitivanje 
nastavljeno je nakon dostupnosti obloge u evaluaciji na 112 slučaja, gdje je obloga pokazala učinkovito kontroliranje 
eksudata i suspektnog biofi lma na ranama koje teško cijele i pri tome poticanje procesa cijeljenja rana i to nakon prosječno 
4 tjedna primjene nove obloge u inače standardnom protokolu njege. To je bilo popraćeno niskim brojem nuspojava. U 
drugoj procjeni bili su evaluirani i klinički znakovi infekcije i podatci o veličini rane, prije i nakon procjene. Nakon prosječno 
5,4 tjedana uporabe obloge, svi su klinički znakovi infekcije bili reducirani, s prosječnom učestalošću od 36 % do 21 %. 
U prosjeku u 62 % rana postignuta je redukcija veličine, uz smanjenje veličine do 90 % i 10 potpuno zacijeljenih rana. 
Najnoviji kliničkih dokazi za novu generaciju antimikrobne obloge za ranu potvrđuju njenu sigurnost i učinkovitost u kontroli 
eksudata, infekcije i biofi lma, a osim toga potvrđuju i zacijeljivanje rana koje dugo i teško ili uopće ne cijele. Znanstvenu 
potporu za najnoviju tehnologiju i generaciju antimikrobne obloge potvrđuju in vitro i in vivo dokazi, tako da su buduća 
komparativna i randomizirana klinička ispitivanja neophodna za potpuno razumijevanje kliničke i ekonomske učinkovitosti 
koju može donijeti ova najnovija tehnologija.
Ključne riječi: rana, biofi lm, infekcija, antimikrobna obloga, anti-biofi lm
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